Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19300079 | 0.82 | OGA (0.67) | OGAALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL24812834 | 0.82 | OGA (0.72) | OGA | |
| SCHEMBL19300267 | 0.73 | OGA (0.66) | OGAALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL16472966 | 0.71 | TSHR (0.62) | KDM4EMCHR1TSHRKCNH2SIGMAR1 | |
| SCHEMBL4125253 | 0.70 | SIGMAR1 (0.62) | MCHR1TSHRSIGMAR1 | |
| SCHEMBL19300081 | 0.69 | MEN1 (0.58) | OGAALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL108678 | 0.69 | KDM4E (0.70) | KDM4ETSHRKCNH2 | |
| SCHEMBL18029422 | 0.68 | ALDH1A1 (0.61) | ALDH1A1HTTKDM4EKCNH2 | |
| SCHEMBL8099486 | 0.68 | TSHR (0.62) | ALDH1A1KDM4EMCHR1TSHRKCNH2 | |
| SCHEMBL4122797 | 0.68 | TSHR (0.62) | ALDH1A1KDM4EMCHR1TSHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | OGA 77/4885ALDH1A1 778/4885LMNA 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.